Gut microbiome, gut function, and probiotics: Implications for health.
New insights from a rapidly developing field of research have ushered in a new era of understanding of the complexity of host-microbe interactions within the human body. The paradigm shift from culturing to metagenomics has provided an insight into the complex diversity of the microbial species that we harbor, revealing the fact that we are in fact more microbes than human cells. The largest consortium of these microbes resides in the gut and is called the gut microbiota. This new science has expanded the ability to document shifts in microbial populations to an unparalleled degree. It is now understood that signals from the microbiota provide trophic, nutritional, metabolic, and protective effects for the development and maintenance of the host digestive, immune, and neuroendocrine system. Evidence linking changes in the gut microbiota to gastrointestinal and extraintestinal disorders like irritable bowel syndrome, inflammatory bowel disease, obesity, diabetes, and celiac disease have begun to emerge recently. Probiotics act through diverse mechanisms positively affecting the composition and/or function of the commensal microbiota and alter host immunological responses. Well-controlled intervention trials, systematic reviews, and meta-analysis provide convincing evidence for the benefit of probiotics in prevention and treatment of gastrointestinal as well as extraintestinal disorders.
Yakult India Microbiota and Probiotic Science Foundation, 52, Okhla Industrial Estate, Phase 3, New Delhi, 110 020, India, neerja.hajela@yakultfoundation.org.in.
Neerja
N
Hajela
B S
BS
Ramakrishna
G Balakrish
GB
Nair
Philip
P
Abraham
Sarath
S
Gopalan
Nirmal K
NK
Ganguly
D004066:Digestive System Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D004700:Endocrine System Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D000069467:Fecal Microbiota Transplantation; D000069196:Gastrointestinal Microbiome / Q000502:physiology; D006801:Humans; D007154:Immune System Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D008659:Metabolic Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D056186:Metagenomics; D009422:Nervous System Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D019936:Probiotics / Q000627:therapeutic use*